SavedAdd your journal

Journals / Türk Dermatoloji Dergisi / 2019 / Cilt: 13 - Sayı: 2

Comparison of Serum Cyclooxygenase‑2 Level between Melasma and Nonmelasma Patients in Dr. Saiful Anwar General Hospital, Malang, Indonesia

Sekar Puspita LİLASARİ
Santosa BASUKİ
Sinta MURLİSTYARİNİ
Pages
9–15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, theseverity of melasma possibly influenced by inflammation markers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Melasma is the hypermelanosis skin disease on the sun exposed area.
📊
Key Findings & Data:Ultraviolet exposure leads to inflammation in theepidermis and dermis, one of which is marked by an increase in Cyclooxygenase-2 (COX-2).
💡
Conclusion & Impact:Therefore, theseverity of melasma possibly influenced by inflammation markers.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Background: Melasma is the hypermelanosis skin disease on the sun exposed area. Ultraviolet exposure leads to inflammation in theepidermis and dermis, one of which is marked by an increase in Cyclooxygenase-2 (COX-2). COX-2 expression involves in the productionof prostaglandin-E2 (PGE2) that take part in tyrosinase activation and melanogenesis. Aims and Objectives: This study aimed to determinethe differences in serum COX-2 levels in melasma and non-melasma patients in Dr. Saiful Anwar General Hospital Malang, Indonesia.Materials and Methods: A cross-sectional study using continuous sampling in melasma and non-melasma patients at the Dermatology andVenereology out-patient clinic from November to December 2017. The COX-2 serum levels examined by ELISA method. Results: Fromthe 23 melasma and 23 non-melasma subjects, the mean value of serum COX-2 levels in the melasma and nonmelasma groups was notsignificantly different (P > 0.05) with value of 82.23±61.08U/L and 52.66±28.62 U/L, respectively. Those might be influenced by the otherunknown variables who were not included in this study. Based on Melasma Severity Score (MSS), serum COX-2 levels differed significantlyin moderate severity (49.55±14.26 U/L) and severe (112.1±72.32 U/L) (P > 0.05) might related to the capacity of the enzyme that inducesepidermal hyperpigmentation. Conclusion: There were differences in COX-2 levels in melasma and non-melasma patients, but the differencewas not statistically significant. However, there is a tendency that as the COX-2 level increases, so as the severity of melasma. Therefore, theseverity of melasma possibly influenced by inflammation markers.

🔖

Cite This Article

LİLASARİ, S. P., BASUKİ, S., MURLİSTYARİNİ, S. (2019). Comparison of Serum Cyclooxygenase‑2 Level between Melasma and Nonmelasma Patients in Dr. Saiful Anwar General Hospital, Malang, Indonesia. Türk Dermatoloji Dergisi, Cilt: 13 - Sayı: 2, 9–15. https://ajindex.com/articles/417158

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Damevska K. New aspects of melasma. Serb J Dermatol Venereol 2014;6:5‑18
  2. Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol 2010;22:373‑8
  3. Ho SG, Chan HH. The Asian dermatologic patient: Review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol 2009;10:153‑68
  4. Handel AC, Lima PB, Tonolli VM, Miot LD, Miot HA. Risk factors for facial melasma in women: A case‑control study. Br J Dermatol 2014;171:588‑94
  5. Soepardiman L. Kelainan pigmen. In: Djuanda A, Hamzah M, Aisah S, editors. Dermatology and Venereal Disease. 5th ed. Jakarta: Balai Penerbit FKUI; 2007
  6. Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res 2018;31:461‑5
  7. Im S, Kim J, On WY, Kang WH. Increased expression of alpha‑melanocyte‑stimulating hormone in the lesional skin of melasma. Br J Dermatol 2002;146:165‑7
  8. Azzam OA, Kadry DM, Rashed LA, Abd El Aziz E, Reham DW. Cyclooxygenase‑2 and prostaglandin E2 in vitiligo patients: Plasma and tissue levels. J Egypt Women Dermatol Soc 2012;9:92‑7
  9. Kim JY, Shin JY, Kim MR, Hann SK, Oh SH. SiRNA‑mediated knock‑down of COX‑2 in melanocytes suppresses melanogenesis. Exp Dermatol 2012;21:420‑5
  10. Rodríguez‑Arámbula A, Torres‑Álvarez B, Cortés‑García D, Fuentes‑Ahumada C, Castanedo‑Cázares JP. CD4, IL‑17, and COX‑2 are associated with subclinical inflammation in malar melasma. Am J Dermatopathol 2015;37:761‑6
  11. PasseronT. Melasma pathogenesis and influencing factors an overview of the latest research. J Eur Acad Dermatol Venereol 2013;27 Suppl 1:5‑6
  12. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the melasma area and severity index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol 2011;64:78‑83, 83.e1‑2
  13. Achar A, Rathi SK. Melasma: A clinico‑epidemiological study of 312 cases. Indian J Dermatol 2011;56:380‑2
  14. Grimes P, Nordlund JJ, Pandya AG, Taylor S, Rendon M, Ortonne JP, et al. Increasing our understanding of pigmentary disorders. J Am Acad Dermatol 2006;54:S255‑61
  15. Ortonne JP, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 2008;13:10‑4
  16. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995;131:1453‑7
  17. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melas